<div id="readability-page-1"><p>Renovorx, Inc. ((RNXT)) has held its Q1 earnings call. Read on for the main highlights of the call.</p><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>RenovoRx’s latest earnings call struck an upbeat tone, with management highlighting record revenue, exceptional gross margins, and a rapidly expanding commercial footprint. Investors also heard about a near-complete Phase III trial and fresh capital that extends the company’s cash runway, though management acknowledged that revenue is still small and execution risks remain.</p> <h2>Record Revenue Marks Inflection in Growth</h2> <p>RenovoRx reported Q1 2026 revenue of $563,000, the highest quarter in its history and a sharp acceleration from previous periods. The figure represents roughly 136% sequential growth from Q4 2025 and 186% year-over-year, with this single quarter already equaling about half of last year’s full-year revenue.</p> <h2>Margin Profile Highlights Attractive Economics</h2> <p>The company delivered gross profit of $479,000 in Q1, translating to a robust gross margin of 85.1%. Such levels suggest the RenovoCath device has compelling unit economics, giving the firm more flexibility to absorb operating expenses as it scales its commercial operations.</p> <h2>Commercial Footprint Expands Across Cancer Centers</h2> <p>RenovoRx now counts 16 active commercial cancer centers as of May 2026, up from just five at the start of 2025 and eight at year-end. Management underscored a pipeline of 32 additional centers in various stages of evaluation, bringing the total prospect list to 48 and supporting a target of 36 active centers by year-end.</p> <h2>Repeat Orders Signal Deepening Physician Adoption</h2> <p>Management emphasized strong repeat order patterns and word-of-mouth advocacy among clinicians as key adoption drivers. The RenovoCath device has already been used in more than 750 procedures since its initial clearance, which the company views as evidence of durable traction and growing comfort among interventional oncologists.</p> <h2>Phase III TIGeR-PaC Trial Nears Full Enrollment</h2> <p>The pivotal TIGeR-PaC study is approaching a major milestone, with 106 of 114 required patients randomized and most required events already observed. Management expects enrollment to close by the end of June 2026, with final data anticipated in mid-to-late 2027, potentially paving the way for broader commercial uptake.</p> <h2>Financing Extends Runway to Support Growth</h2> <p>RenovoRx reinforced its balance sheet in March with an oversubscribed private placement that raised about $10 million in gross proceeds. Combined with existing resources, cash and equivalents totaled roughly $12.4 million at quarter-end, which management believes will fund operations into the second half of 2027.</p> <h2>Scientific Data and New Trials Build Validation</h2> <p>The company highlighted fresh scientific support, including a sub-study from TIGeR-PaC presented at a major gastrointestinal oncology meeting. That work showed reduced systemic exposure to gemcitabine with its targeted delivery approach, and two new investigator-initiated trials in metastatic and borderline resectable pancreatic cancer have been cleared, broadening clinical interest.</p> <h2>Operating Expenses Underscore Investment Phase</h2> <p>RenovoRx remains firmly in investment mode, with Q1 research and development expenses at $1.2 million and selling, general and administrative costs around $2.7 million. Management noted some timing-related deviations versus internal plans, but operating burn remains significant relative to current revenue.</p> <h2>Reliance on Conversions Keeps Revenue Base Fragile</h2> <p>Despite impressive growth rates, the company’s revenue base is still modest at $563,000 for the quarter. Hitting the full-year targets will require consistent conversion of pipeline centers into active users and sustaining procedure volumes, leaving results sensitive to adoption pacing.</p> <h2>Trial and Revenue Timing Pose Execution Risk</h2> <p>Management acknowledged that both clinical and commercial timelines carry uncertainties, with the TIGeR-PaC trial still needing final events and readout in 2027. Revenue has historically been “chunky,” driven by the timing of center approvals and orders, and while the company expects smoother trends over time, near-term volatility is possible.</p> <h2>Manufacturing Optimization Still on the To-Do List</h2> <p>The call also touched on planned device and manufacturing optimizations aimed at lowering costs of goods sold and supporting scale. These changes are described as incremental and not expected to disrupt current operations, but they will demand continued operational and R&amp;D attention.</p> <h2>Cash Runway Strong but Not Unlimited</h2> <p>While the extended cash runway into the second half of 2027 is a clear positive, management conceded that a slower-than-expected revenue ramp could necessitate fresh capital. The company’s path to cash-flow breakeven therefore hinges on timely center conversions, procedure growth, and successful clinical milestones.</p> <h2>Guidance Underscores Confidence in Growth Trajectory</h2> <p>RenovoRx reiterated its full-year 2026 revenue outlook of $3.0 million to $4.0 million and guided that Q2 revenue should exceed the Q1 record. Management is leaning on the expanding base of 16 active centers, a robust pipeline of 32 more in evaluation, and the expected completion of trial enrollment to support this growth, while recent financing helps bridge the company toward its profitability ambitions.</p> <p>RenovoRx’s earnings call painted the picture of a company at an inflection point, combining strong early commercialization with ongoing clinical and financial risks. For investors, the story hinges on whether the firm can convert its growing pipeline of centers into steady revenue and deliver positive Phase III data, but for now the momentum leans firmly in its favor.</p></div>

RNXT

<p>RenovoRx, Inc. reported record Q1 2026 revenue of $563,000, marking a 136% sequential growth. The company highlighted strong gross margins of 85.1% and an expanding commercial footprint with 16 active cancer centers. A pivotal Phase III trial is nearing full enrollment, and recent financing extends its cash runway into 2027. Despite impressive growth, management acknowledged execution risks and the need for consistent center conversions to sustain revenue growth. The company maintains a full-year revenue outlook of $3.0 million to $4.0 million.</p>

RenovoRx Earnings Call Signals Commercial Inflection